Skip to content

TransMedics

US · TMDX #2536 by market cap Listed 2019
85.25 -8.77 -9.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 90.20 -4.06%
After-hours 85.60 +0.41%
Overnight 94.02 0.00%
96.4365.9985.252026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TMDX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -18.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 25.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 23.2x Better than 33%
Forward P/E 32.5x Better than 15%
Price / Sales 4.4x Better than 26%
P/E vs own 5-yr range 67th pctl Better than 41%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 59.9% Better than 74%
Operating margin 17.9% Better than 72%
Net margin 31.4% Better than 91%
Return on equity 54.2% Better than 95%
Return on invested capital 23.1% Better than 93%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -10.0% Better than 51%
6-month return 23.7% Better than 86%
12-month return (ex latest month) -46.0% Better than 4%
Distance below 52-week high 45.4% Better than 23%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.1x Better than 91%
Debt to assets 48.6% Better than 17%
Interest coverage 8.8x Better than 70%
Free cash flow / net income 70.2% Better than 21%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 77.8% Better than 57%
Upside to average target 22.9% Better than 38%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.71%
1M +14.05%
3M -6.16%
6M +25.37%
YTD -29.92%
1Y -31.15%
3Y +22.06%
5Y +274.07%

Key statistics

Price & volume

Prev close
94.02
Open
90.81
Day range
83.89 - 91.62
Avg price
86.44
Volume
1.59M
Turnover
137.27M
Amplitude
8.22%
52-week range
60.11 - 156.00

Valuation

P/E
17.51
P/E (TTM)
23.23
P/B
5.38
EPS
4.87
Net profit
169.15M
Net assets
550.71M

Share structure

Market cap
2.96B
Float cap
2.87B
Shares out
34.73M
Float shares
33.62M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-05-02
52-week range 26% of range
60.11 156.00

45.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.83M net over the window

Short interest

Shares short
8.88M
As of
2026-10-30

Frequently asked questions

What is the current stock price of TransMedics (TMDX)?

TransMedics last traded at 85.25. This page shows a periodic quote snapshot. Check the displayed quote time.

What is TransMedics's market cap?

About 2.96B.

What is the P/E ratio of TransMedics?

The trailing twelve-month P/E is 23.23, below its own 5-year average of 159.86 — toward the top of its historical range (67.30% percentile). See the Valuation tab for the full history.

Does TransMedics pay a dividend?

TransMedics does not currently pay a regular dividend.

Is TransMedics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 104.75, which implies 22.9% upside from the current price. This is not investment advice.

What is TransMedics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates TransMedics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

TransMedics discussion 0 comments

Add a comment